leisure time -WSS

leisure time

author：Wikipedia 2025-10-03 00:08:20 - browse：451

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Listen: Who gets the credit for GLP

leisure time

WSS

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

How the Dana

Biogen shutters digital health group, ends Apple study, in cost cutting move

Shingles, which affected Dianne Feinstein, is on the rise

Data show record exodus of life scientists from academia

Gene therapy denied for Afghan refugee whose father aided U.S.

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

Sudafed saga points to U.S. issues with evaluating older drugs

Bright Health sells Medicare Advantage business to Molina

Profiling embryos to choose those with higher IQs is almost a reality

DIEP, the 'gold standard' of breast reconstruction, is under threat

Does Paxlovid work in people vaccinated against Covid

Anesthesiologist group: stop taking Ozempic before surgery

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

What does generative AI mean for health care? We asked experts

How one patient went off dialysis — and others can too

entertainment

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Biogen shutters digital health group, ends Apple study, in cost cutting move

Biogen shutters digital health group, ends Apple study, in cost cutting move

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Did you have Obamacare on your GOP debate bingo card?

Data show record exodus of life scientists from academia

Wikipedia

Wikipedia

leisure time

focus